How to Get Enclomiphene Citrate in Virginia

What Is Enclomiphene Citrate and Why Virginia Men Are Seeking It

Enclomiphene citrate is the trans-stereoisomer of clomiphene. It acts as a selective estrogen receptor modulator (SERM) at the hypothalamus and pituitary, blocking negative estrogen feedback and raising endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This drives the testes to produce more testosterone without suppressing sperm production, the way exogenous testosterone does.

Kim et al. (BJU International, 2016, N=303) compared enclomiphene citrate to testosterone gel in men with secondary hypogonadism and found that enclomiphene raised mean serum testosterone from 230 ng/dL to 412 ng/dL at 12 weeks while preserving sperm counts, whereas testosterone gel suppressed sperm concentration by roughly 50% over the same period [1]. That fertility-preserving property is a core reason Virginia men who want symptom relief without closing the door on future conception choose this compound.

The drug has no FDA-approved brand-name product currently on the market. Androxal (enclomiphene citrate, Repros Therapeutics) received two Complete Response Letters from the FDA, most recently in 2013 [2]. Because no finished dosage form is commercially available, all prescriptions are filled by compounding pharmacies operating under 503A of the Federal Food, Drug, and Cosmetic Act [2].

Symptoms that typically bring patients to a provider include morning fatigue that persists despite adequate sleep, reduced libido, difficulty maintaining muscle mass at a stable training volume, and mood changes consistent with hypogonadism on validated scales such as the ADAM questionnaire [3]. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends confirming a low testosterone level on at least two morning measurements before initiating any treatment [4].

Virginia Law and Telehealth Prescribing Rules

Virginia law permits telehealth prescribing of enclomiphene citrate. The Virginia Board of Medicine allows controlled and non-controlled prescriptions issued via synchronous audio-video telehealth after a valid patient-provider relationship is established [5]. Enclomiphene citrate is not a scheduled substance under the Virginia Drug Control Act or the federal Controlled Substances Act, so prescribers face no DEA registration barrier specific to this compound.

Under Virginia Code and the Board of Medicine's telehealth guidance, the provider must perform a real-time audio-video evaluation sufficient to support a diagnosis. A text-only or asynchronous encounter does not satisfy this standard for a new prescription. The provider must also review lab results, take a medication history, and document a clinical impression before sending the prescription [5].

Nurse practitioners holding a Nurse Practitioner license with prescriptive authority in Virginia may prescribe enclomiphene without a physician co-signature, provided they hold an active Collaborative Practice Agreement or have been in practice long enough to qualify for independent prescriptive authority under Virginia law [6]. Licensed physician assistants may prescribe under the supervision of a licensed Virginia physician per the Board of Medicine's PA prescribing regulations [6].

Out-of-state telehealth providers must hold a Virginia medical license or a Virginia telemedicine certificate to prescribe to Virginia patients [5]. Verify licensure on the Virginia Department of Health Professions website before scheduling.

Required Labs Before Your First Prescription

Labs are not optional. Every reputable provider will require baseline bloodwork before prescribing, both for patient safety and to satisfy Virginia Board of Medicine documentation standards for hypogonadism treatment [4].

The minimum panel includes total serum testosterone (two morning draws, ideally on separate days), LH, FSH, estradiol (sensitive assay), prolactin, CBC, and a comprehensive metabolic panel. Many providers also order free testosterone (equilibrium dialysis method), sex hormone-binding globulin (SHBG), and a lipid panel. The Endocrine Society's 2018 guideline states that "biochemical diagnosis of hypogonadism requires demonstration of consistently low serum testosterone concentrations" and specifies that samples should be drawn between 7:00 and 10:00 AM [4].

LH and FSH levels are particularly important for enclomiphene candidacy. Secondary hypogonadism is defined by low testosterone paired with low or inappropriately normal LH and FSH, indicating a hypothalamic-pituitary axis problem rather than primary testicular failure [4]. Enclomiphene works by stimulating that axis. If LH and FSH are already elevated and testosterone is still low, the testes are not responding, and enclomiphene will not help [1].

A 2020 review in the Journal of Clinical Endocrinology and Metabolism noted that secondary hypogonadism accounts for approximately 40% of hypogonadism cases in men presenting to endocrinology clinics, making it a sizable candidate pool for SERM-based therapy [7]. Estradiol should be measured at baseline because enclomiphene can raise estradiol as testosterone rises; providers titrate dose to keep estradiol below 40 pg/mL on most protocols [1].

Prolactin elevation signals a pituitary adenoma and must be ruled out before any SERM therapy begins. A serum prolactin above 25 ng/mL typically prompts pituitary MRI before prescribing [4].

How to Find a Virginia Provider Who Prescribes Enclomiphene

Several pathways exist. Patients can see a board-certified urologist or endocrinologist in person at major Virginia health systems such as VCU Health, Inova, Sentara, or UVA Health. Wait times at academic centers run 4 to 12 weeks for a new patient appointment [8].

Telehealth platforms licensed in Virginia offer faster access. HealthRX providers licensed in Virginia conduct audio-video consultations, review uploaded lab results, and send compounding pharmacy prescriptions the same day if labs support the diagnosis. This compresses the timeline to first prescription to 24 to 72 hours after lab review.

The table below outlines a practical decision framework for Virginia patients choosing between in-person and telehealth access:

Virginia Enclomiphene Access Decision Framework

| Factor | In-Person Specialist | Telehealth Provider | |---|---|---| | Wait time for first appointment | 4 to 12 weeks | 24 to 72 hours | | Labs drawn on-site | Yes | Patient uses LabCorp/Quest order | | Semen analysis coordination | Easy | Requires local lab referral | | Prior authorization help | Billing team on-site | Varies by platform | | Cost without insurance | $250 to $500 per visit | $75 to $200 per visit |

Regardless of route, confirm the provider will write to a 503A compounding pharmacy and will provide follow-up labs at 6 and 12 weeks, which is the standard monitoring interval for testosterone and estradiol response [4].

Virginia 503A Compounding Pharmacies and How the Prescription Gets Filled

Because no commercially manufactured enclomiphene citrate product is FDA-approved and on pharmacy shelves, every prescription in Virginia is filled by a 503A compounding pharmacy. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare drug products from bulk active pharmaceutical ingredients for individual patients with a valid prescription [2].

Virginia-licensed 503A pharmacies may ship compounded enclomiphene to Virginia patients, provided the prescription is patient-specific and the pharmacy holds an active Virginia Board of Pharmacy license [9]. The Virginia Board of Pharmacy does not restrict interstate receipt of compounded non-scheduled drugs for personal use when the dispensing pharmacy is licensed in its home state, though patients should confirm the compounding pharmacy holds Virginia dispensing authorization [9].

Typical compounded forms are oral capsules (25 mg, 50 mg) or sublingual tablets. Most protocols start at 12.5 mg to 25 mg once daily and adjust based on 6-week testosterone and estradiol levels [1]. Monthly cost for compounded enclomiphene at most Virginia-serving pharmacies ranges from $60 to $120 for a 30-day supply, though prices vary by pharmacy and formulation.

The FDA's guidance on compounding from bulk drug substances distinguishes 503A (patient-specific, physician-initiated, small-batch) from 503B (outsourcing facilities that can compound without a patient-specific prescription) [2]. Enclomiphene citrate bulk API is currently on the FDA's 503A Bulks List under consideration, meaning it may be compounded under 503A while the agency reviews its status [2]. Patients and providers should monitor FDA updates, as removal from the bulks list would affect availability.

Quality matters when choosing a compounding pharmacy. Look for PCAB (Pharmacy Compounding Accreditation Board) accreditation and ask for a Certificate of Analysis (CoA) confirming API purity of 98% or higher for each lot [10].

Dosing, Titration, and Monitoring in Virginia Practice

Starting doses in published studies and clinical practice range from 12.5 mg to 25 mg once daily. Kim et al. used 12.5 mg and 25 mg arms in their 12-week trial and found both doses raised testosterone significantly above placebo, with the 25 mg dose producing a mean testosterone of 412 ng/dL compared with 234 ng/dL at baseline [1]. The Endocrine Society guideline target for testosterone replacement in hypogonadal men is the mid-normal range, roughly 400 to 700 ng/dL [4].

Follow-up labs at 6 weeks should include total testosterone (morning draw), LH, FSH, estradiol, and a CBC. If testosterone is below 400 ng/dL and the patient tolerates the current dose, the provider may increase to 50 mg daily. If estradiol exceeds 40 pg/mL, the provider may lower the dose or add a low-dose aromatase inhibitor such as anastrozole 0.25 mg twice weekly [1].

A 2013 randomized controlled trial (N=124) published in the International Journal of Impotence Research found that 12 weeks of enclomiphene 25 mg daily normalized testosterone in 70% of men with secondary hypogonadism [11]. Symptom improvement on the ADAM questionnaire lagged biochemical normalization by roughly 4 weeks, so patients should not expect immediate symptom relief [11].

Annual monitoring after stabilization typically includes testosterone, estradiol, CBC (hematocrit surveillance), PSA in men over 40, and a lipid panel. The Endocrine Society recommends hematocrit monitoring because estrogen receptor modulation can modestly raise erythropoiesis, though the effect is smaller than seen with exogenous testosterone [4].

Virginia Medicaid Prior Authorization for Enclomiphene

Virginia Medicaid covers compounded enclomiphene citrate for secondary hypogonadism as an off-label use, but coverage requires prior authorization (PA). The process involves submitting clinical documentation through the Virginia Medicaid Health Plan's PA portal, and requirements vary slightly by managed care organization (Aetna Better Health of Virginia, Anthem HealthKeepers Plus, Molina Healthcare of Virginia, Optima Family Care, or United Healthcare Community Plan of Virginia) [12].

Standard PA documentation requirements across Virginia Medicaid plans include:

1. Two morning serum testosterone results below 300 ng/dL, drawn on separate days.
2. LH and FSH levels confirming secondary (not primary) hypogonadism.
3. Documentation that the patient has symptomatic hypogonadism based on a validated questionnaire or clinical notes.
4. Prescriber attestation that commercially available testosterone products are not appropriate (for example, due to fertility preservation goals).
5. The specific compounded formulation, dose, and 30-day supply quantity requested.

PA decisions typically take 3 to 5 business days for standard review or 24 hours for expedited review when a provider documents clinical urgency [12]. If denied, Virginia Medicaid enrollees have the right to a fair hearing under federal Medicaid regulations [12].

Patients with commercial insurance should check their plan's specialty drug tier. Most commercial plans in Virginia classify compounded enclomiphene as a non-covered compounded drug, meaning out-of-pocket cost applies. Some plans with flexible spending account (FSA) or health savings account (HSA) provisions allow enclomiphene costs to be paid pre-tax [13].

Transferring an Existing Enclomiphene Prescription to Virginia

Patients relocating to Virginia with an existing enclomiphene prescription from another state face a straightforward process. The original prescribing provider, if not licensed in Virginia, cannot continue issuing Virginia prescriptions after the patient establishes residency [5]. The patient must establish care with a Virginia-licensed provider.

Most telehealth platforms can transfer clinical records from a prior provider and conduct a shorter intake visit focused on reviewing previous labs and response rather than a full diagnostic workup, provided labs are recent (within 3 to 6 months) [5]. Bring documentation of your current dose, the compounding pharmacy you use, and your most recent testosterone and estradiol results to the new patient visit.

The prescription itself cannot be physically transferred to a new pharmacy under a non-Virginia prescriber's authority. A Virginia provider must issue a new prescription. If your current compounding pharmacy is licensed to ship to Virginia and the new provider sends a new script, you may continue using the same pharmacy without interruption [9].

Side Effects, Contraindications, and Safety Considerations

Enclomiphene is generally well tolerated at clinical doses. Reported side effects in Kim et al. included mild headache (8% in the 25 mg group vs. 5% placebo), transient visual disturbances (2%), and mood changes (4%) [1]. Visual symptoms such as blurring or photophobia warrant immediate discontinuation and ophthalmology referral; this adverse effect is shared with clomiphene and relates to SERM activity at retinal receptors [14].

Contraindications include known hypersensitivity to clomiphene or related SERMs, active liver disease (enclomiphene undergoes hepatic metabolism), and hormone-sensitive malignancies. Men with a prior or active testicular germ cell tumor should not use any SERM without oncology clearance [4].

Enclomiphene raises estradiol as it raises testosterone. Men with a baseline estradiol above 50 pg/mL or symptomatic gynecomastia may not be good candidates until estrogen is managed [1]. A 2019 systematic review in Therapeutic Advances in Urology covering SERM use in male hypogonadism (N=9 trials, 743 patients) found that gynecomastia rates with enclomiphene were under 3%, substantially lower than rates reported with clomiphene [15].

The drug has not been studied in men over 65 in randomized trials; use in older men with prostate disease requires individual risk-benefit discussion and PSA monitoring [4].

Getting Started: Step-by-Step for Virginia Residents

The practical sequence for most Virginia patients is as follows. Order baseline labs first, either through your primary care provider or through a direct-to-patient lab service such as LabCorp or Quest using an online requisition. Request total testosterone (morning draw), free testosterone, LH, FSH, estradiol (sensitive), prolactin, SHBG, CBC, CMP, and lipid panel.

Schedule your telehealth or in-person consultation after you have results in hand. Upload results before the visit so the provider can review them in advance and use the visit time for clinical discussion. During the visit, be prepared to describe symptom duration, prior testosterone treatments, current medications (particularly opioids, glucocorticoids, or anabolic steroids, which suppress the HPG axis [16]), and reproductive goals.

If the provider diagnoses secondary hypogonadism and enclomiphene is appropriate, the prescription goes to a Virginia-licensed 503A compounding pharmacy that day. Most Virginia-serving compounding pharmacies ship within 3 to 5 business days of receiving a verified prescription [9]. Follow-up labs at 6 weeks complete the first monitoring cycle, and the provider adjusts dose based on results.

The Endocrine Society specifies that after initiating any testosterone-axis therapy, a follow-up assessment should occur "at 3 to 6 months after initiating treatment, then annually" [4]. Enclomiphene providers following this guideline will schedule a 6-week biochemical check and a 12-week clinical reassessment as the minimum standard of care for Virginia patients.